

REMARKS

Applicant wishes to thank the Examiner for the consideration given this case to date. Applicant has now had an opportunity to carefully consider the Examiner's action, and respectfully submits that the application, as amended, is now in condition for allowance. Currently, claims 1-13, 19-23 are pending.

THE EXAMINER'S ACTION

In the Office Action dated August 25, 2004, the Examiner:

- rejected claims 1-13 and 19-23, but indicated allowable subject matter and suggested claim changes that would facilitate allowance of the claims; the suggestions are as follows:
 - provide terminal disclaimer over 09/580,110;
 - remove "comprising" language from claims 1 and 19-23;
 - utilize suggested language for claim 1, "A pharmaceutical or cosmetic composition comprising peptide of SEQ ID NO. 48";
 - cancel claims 6 and 7;
 - in claim 8, replace "peptide" with "the composition";
 - cancel claim 12
 - in claim 13, remove "comprising a peptide"; and
 - in claim 13, line 2, description of SEQ ID NO. 42: remove "Alanine-


TERMINAL DISCLAIMER

Applicants faxed a terminal disclaimer to Examiner Borin on July 28, 2004 at (703) 872-9306 and received confirmation of receipt at the Patent Office by Auto-Reply Facsimile Transmission at 4:30:59 PM on July 28, 2004. Enclosed with this response is a copy of the previously faxed terminal disclaimer.

CONCLUSION

Applicants have made the suggested claim changes to facilitate allowance. Applicant respectfully asserts that the case is now in condition for allowance. The Commissioner is hereby authorized to charge any additional fees or credit any overpayments to Deposit Account 02-2051 referencing Attorney Docket No. 25812-5-CIP.

Dated: 5 Nov 2004

By: 
W. Scott Harders
Reg. No. 42,629

BENESCH, FRIEDLANDER,
COPLAN & ARONOFF LLP
2300 BP Tower
200 Public Square
CLEVELAND, OH 44114-2378
(216) 363-4443